2012/13 Tender Consultation - Suppliers; Contact: Marcus Kim (text extract)

This is the text extract for 2012/13 Tender Consultation - Suppliers; Contact: Marcus Kim, browse documents here.

19 July 2012

2012/13 Invitation to Tender

PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on:    A proposal to tender certain pharmaceuticals for sole supply; The draft process and terms and conditions for the 2012/13 Invitation to Tender (2012/13 Tender); and Commercial proposals as an alternative to tendering.

PHARMAC welcomes all feedback on the draft 2012/13 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or Chief Executive acting under Delegated Authority) prior to making a decision on this proposal. Feedback should be submitted by the following dates; late feedback may not be considered:

ALTERNATIVE COMMERCIAL PROPOSAL RESPONSES DUE BY 5 PM, THURSDAY 16 AUGUST 2012 ALL OTHER CONSULTATION RESPONSES DUE BY 5 PM, THURSDAY 30 AUGUST 2012

Feedback should be provided by submitting an email, fax or letter to: Marcus Kim Tender Analyst PHARMAC PO Box 10-254 Wellington 6143 Details of the proposed 2012/13 Tender In general, the proposed 2012/13 Tender process would be similar to the 2011/12 Tender. In addition to Alternative Commercial Proposals (discussed below), we seek comments on all sections of the draft 2012/13 Tender, in particular on:   The proposed changes to the 2012/13 Tender; An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2012/13 Tender, that you consider should be tendered, and the reasons for that view. If you wish, you may provide a non-binding confidential indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered; An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2012/13 Tender, that you consider would be inappropriate to tender, Email: marcus.kim@pharmac.govt.nz Fax: (04) 460 4995 DDI: (04) 916 7263



and the reasons for that view, including any contractual constraints or patent protection that could restrict PHARMAC from awarding a tender on a particular pharmaceutical; For Hospital Pharmaceuticals, feedback on the appropriate Discretionary Variance Limit for each pharmaceutical, in the event that a 1% Discretionary Variance Limit is not considered clinically acceptable; and Feedback on any unresolved Tender Bid(s) from previous tenders that you consider should remain open for acceptance.

Draft Invitation to Tender We are seeking feedback on the composition of the draft 2012/13 Tender. This is still under development and may change before it is taken to the Board for approval and subsequently issued. At this stage, but depending on the extent of any changes, PHARMAC does not intend to send out further drafts for consultation. A complete copy of the draft 2012/13 Tender, including the proposed terms and conditions which successful tender bids would be subject to, is available on our website (www.pharmac.govt.nz). The draft 2012/13 Tender comprises the following sections: Schedule 1: Schedule 2: Schedule 3: Schedule 4: Schedule 5: Schedule 6: Definitions and interpretation The list of pharmaceuticals proposed for tender* # The Tender process (for both hospital and community Tenders) Contract terms for Sole Subsidised Supply and/or Hospital Supply Status Additional contract terms for Sole Subsidised Supply Status Additional contract terms for Hospital Supply Status

* The market data for the year ended 30 June 2012 provided in Schedule Two has not yet been finalised and is partially based on forecasts; however, finalised data would be included in the final 2012/13 Tender. The figures included are indicative only and are provided on the basis set out in clause 1.3 of Schedule 2 of the draft 2012/13 Tender. # The final list of products, which may change following consultation, would be released as part of the 2012/13 Tender, following Board approval. You may provide feedback on the inclusion of any additional pharmaceuticals after the 2012/13 Tender has been issued, and any such feedback would be considered by the Board (or Chief Executive under Delegated Authority) before making a final decision on any product, provided that any feedback is given prior to the tender close date in late 2012.

Key Dates and Timeframes for the 2012/13 Tender: The timelines for the 2012/13 Tender are envisaged to be similar to the 2011/12 Tender; we propose to release the final 2012/13 Invitation to Tender in early November 2012 and consequently the closing date for tender submissions would be late December 2012. The proposed timeline is outlined in the following table:

Date 19 July 2012 16 August 2012 30 August 2012 Event Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC. Final date for all consultation to be received.

September 2012

PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC’s Decision Criteria and enters into provisional contracts with suppliers where appropriate. Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. Consultation and Board decisions on Alternative Commercial Proposals. Issuing of the 2012/13 Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced.

September 2012 September/October 2012 Early November 2012 19 December 2012 From end of January 2013

Unresolved Tender Bids We intend to review any unresolved Tender Bids from the 2010/11 Tender and the 2011/12 Tender prior to issuing the 2012/13 Tender. The following Tender Bids remain unresolved: 2010/11 Invitation to Tender

Chemical Name Amikacin Carbomer Magnesium Sulphate Pamidronate Disodium Pamidronate Disodium Pamidronate Disodium Paracetamol Paracetamol Tenoxicam Inj 5 mg per ml, 5 ml Opthalmic gel Inj 49.3%, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Inj 9 mg per ml, 10 ml Inj 10 mg per ml, 100 ml Inj 10 mg per ml, 50 ml Tab 20 mg Line Item

2011/12 Invitation to Tender

Chemical Name Amoxycillin Amoxycillin Aripiprazole Aripiprazole Aripiprazole Aripiprazole Atropine Sulphate Baclofen Brinzolamide Bupivacaine Hydrochloride Cephalexin Monohydrate Cephalexin Monohydrate Chlorhexidine Gluconate Chlorhexidine Gluconate Cholecalciferol Clonidine Clonidine Clonidine Clonidine Clonidine Clonidine Domperidone Doxorubicin Doxorubicin Doxorubicin Glipizide Glycerol Granisetron Granisetron Hydrocortisone Acetate Hydroxychloroquine Sulphate Intra-Uterine Device Intra-Uterine Device L-Carnitine Lignocaine Hydrochloride Lignocaine Hydrochloride Lignocaine Hydrochloride Line Item Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 10 mg Tab 15 mg Tab 20 mg Tab 30 mg Inj 600 mcg, 1 ml Tab 10 mg Eye Drops 1% Inj 0.5%, 10 ml Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Handrub 0.5% - 1% with ethanol 70% Mouthwash 0.2% Tab 1.25 mg (50,000 iu) Tab 150 mcg Tab 150 mcg Tab 25 mcg TDDS 2.5 mg, 100 mcg per day TDDS 5 mg, 200 mcg per day TDDS 7.5 mg, 300 mcg per day Tab 10 mg Inj 200 mg Inj 50 mg Powder for inj, 50 mg Tab 5 mg Suppos greater than 3 g Inj 1 mg Tab 1 mg Rectal foam 10%, CFC-free Tab 200 mg IUD - Short length (5 - 8 cm) IUD - Standard length (6 - 9 cm) Tab 300 mg - 500 mg Inj 1%, 2 ml Inj 1%, 20 ml Inj 1%, 5 ml Chemical Name Lignocaine Hydrochloride Lignocaine Hydrochloride Lignocaine Hydrochloride Methotrexate Methotrexate Moclobemide Moclobemide Morphine Sulphate Morphine Sulphate Nadolol Nadolol Naproxen Naproxen Nortriptyline Hydrochloride Nortriptyline Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxycodone Hydrochloride Oxytocin Oxytocin Pancuronium bromide Paracetamol Paraffin Pizotifen Prednisolone Sodium Phosphate Quinapril Quinapril Quinapril Tranexamic Acid Travoprost Tropisetron Tropisetron Line Item Inj 2%, 2 ml Inj 2%, 20 ml Inj 2%, 5 ml Tab 10 mg Tab 2.5 mg Tab 150 mg Tab 300 mg Tab immediate release 10 mg Tab immediate release 20 mg Tab 40 mg Tab 80 mg Tab 250 mg Tab 500 mg Tab 10 mg Tab 25 mg Cap 10 mg Cap 20 mg Cap 5 mg Inj 50 mg per ml Tab controlled-release 10 mg Tab controlled-release 20 mg Tab controlled-release 40 mg Tab controlled-release 5 mg Tab controlled-release 80 mg Inj 10 iu per ml, 1 ml Inj 5 iu per ml, 1 ml Inj 2 mg per ml, 2 ml Suppos 500 mg White soft or yellow soft (pack size 30 g or less) Tab 500 mcg Oral liq 5 mg per ml Tab 10 mg Tab 20 mg Tab 5 mg Inj 100 mg per ml, 5 ml Eye drops 0.004% Inj 1 mg per ml, 2 ml Inj 1 mg per ml, 5 ml

A518829 - qA25122

Should any unresolved Tender Bids be declined prior to the release of the 2012/13 Tender, PHARMAC would consider re-tendering those pharmaceuticals when the 2012/13 Tender is issued. Unresolved Tender Bids have not been included in the draft pharmaceutical list (Schedule Two). Products not currently listed on the Pharmaceutical Schedule The following products included in Schedule Two of the draft 2012/13 Tender are not currently listed on the Pharmaceutical Schedule:

Chemical Name Baclofen Benzbromarone Benzoyl Peroxide# Benzoyl Peroxide# Bimatoprost with timolol* Dimethicone# Dimethicone# Heparin Sodium Heparinised Saline# Heparinised Saline# Hydrocortisone Butyrate# Hydrocortisone Butyrate# Indomethacin# Indomethacin# Indomethacin# Latanoprost with timolol* L-Carnitine* L-Carnitine* L-Carnitine* Methotrexate* Methotrexate* Line Item Oral liq 1 mg per ml Tab 100 mg Gel 5% Gel 2.5% Eye Drops 0.03% with timolol 0.5% Crm 10% BPC Crm 5% Inj 100 iu per ml, 250 ml Inj 100 iu per ml, 2 ml ampoule Inj 100 iu per ml, 5 ml ampoule Milky Emulsion 0.1% (pack size 30 g or less) Oint 0.1% (pack size 30 g or less) Cap 25 mg Cap 50 mg Cap long-acting 75 mg Eye drops 50 mcg per ml with timolol 0.5% Inj 200 mg per ml Oral liquid 500 mg per 15 ml Powder Inj 40 mg prefilled syringe Inj 30 mg prefilled syringe Chemical Name Methotrexate* Methotrexate* Methotrexate* Methotrexate* Mupirocin Nicotinic Acid Nicotinic Acid Nicotinic Acid Nicotinic Acid Nitrofurantoin Oestradiol Doxorubicin Doxorubicin Phenobarbitone# Pipobroman Pramipexole Hydrochloride Rosuvastatin Rosuvastatin Rosuvastatin Rosuvastatin Travoprost with timolol Valaciclovir Valaciclovir Line Item Inj 25 mg prefilled syringe Inj 20 mg prefilled syringe Inj 10 mg prefilled syringe Inj 7.5 mg prefilled syringe Nasal oint 2% Tab modified-release 750 mg Tab modified-release 375 mg Tab modified-release 500 mg Tab modified-release 1 g Oral liq 25 mg per 5 ml# TDDS 75 mcg per day Inj pegylated liposomal 20 mg Inj pegylated liposomal 50 mg Oral liq 15 mg per 5 ml Tab 25 mg Tab 1 mg Tab 5 mg Tab 10 mg Tab 20 mg Tab 40 mg Eye drops 0.004% with timolol 0.5% Tab 250 mg Tab 1000 mg

Products marked with an “*” have been considered for funding by the Pharmacology and Therapeutic Advisory Committee (PTAC) or the relevant Subcommittee of PTAC; however, these products, and the remainder of the chemicals in the list above, may be considered further by PTAC and/or its Subcommittees after tender bids have been received. Products marked with an “#” have been listed on the Pharmaceutical Schedule previously. Electronic Tender (eTender) system The 2012/13 Invitation to Tender will be distributed via PHARMAC’s eTender system. Please let us know by 5pm, 28 September 2012 if the contact details for the person responsible for submitting tender bids have changed for your company or if you would like to register your company to use the eTender system.

A518829 - qA25122 5

Implications of “Lead Time” As with previous tenders, suppliers (especially incumbent suppliers) are advised to be aware of the implications of a short Lead Time when submitting your tender bids. For your ease of reference, the relevant terms and conditions contained in the draft 2012/13 Tender as follows (emphasis added): Schedule 1: Definitions and interpretation Lead Time means the number of months (being whole months only) indicated on your Tender Bid that, if your Tender Bid is accepted, you would require following the Successful Tenderer Notification Date in order to source sufficient stock of your brand of the Tender Item to meet the entire market demand for the Tender Item as at the Start Date. For the avoidance of doubt, the Lead Time does not affect, and should incorporate the extra time needed to allow for, your obligations in clause 3.1 of Schedule 5 and clause 3.1 of Schedule 6 to have stock of the Pharmaceutical available for supply or sale, and supply or sell the Pharmaceutical, at the Price from the 12th day of the month prior to the Start Date; Start Date means: (a) in relation to a Tender Item for which your Tender Bid has been accepted unconditionally, the first day of the month following the date that represents: (i) the Successful Tenderer Notification Date; plus (ii) the Lead Time; or (b) in relation to a Tender Item for which your Tender Bid has received conditional acceptance, in terms of clause 7.4 of Schedule Three, the first day of the month following the date that represents: (i) the date that such acceptance ceases to be conditional; plus (ii) the Lead Time; or (c) such other date that is negotiated between you and PHARMAC under clause 1.6 of Schedule Three;

Schedule 5: Additional contract terms for Sole Supply Status Clause 3.1 - Price change (a) You must change the price at which you supply the Pharmaceutical to the Price on the 12th day of the month prior to the Start Date. If your brand of the Pharmaceutical is not listed on the Pharmaceutical Schedule at the beginning of the First Transition Period, it must be available for supply and you must supply the Pharmaceutical, at the Price from the 12th day of the month prior to the Start Date, and will be subsidised at the Price from the Start Date; and You must ensure that wholesalers and other such distributors change the price at which they supply the Pharmaceutical to the Price (plus any mark-ups and GST) on the 12th day of the month prior to the Start Date.

(b)

A518829 - qA25122

Material changes to the 2012/13 Tender The following changes are proposed to the 2012/13 Tender:  Schedule 6 includes a new clause (clause 8.2) relating to PHARMAC’s activities to assume responsibility for decision-making on the funding of hospital pharmaceuticals. From July 2013, Section H will include national prescribing and/or dispensing restrictions for some products. Consultation and decision-making on restrictions for some products would occur after tender bids are submitted.

Alternative Commercial Proposals PHARMAC seeks any Alternative Commercial Proposals (ACPs) to tendering that you may wish to submit. An ACP may, for example, offer price reductions on one set of pharmaceuticals in return for PHARMAC agreeing to defer tendering on another group of pharmaceuticals for a period. Please note the following points apply to ACPs for both the community and DHB hospital markets:   ACPs may include more than one line item and may include pharmaceuticals not listed in Schedule Two of the draft 2012/13 Tender; ACPs may seek PHARMAC’s agreement to defer tendering or application of reference pricing for a period of time for any pharmaceutical, whether or not it is listed in Schedule Two of the draft 2012/13 Tender; ACPs may propose PHARMAC awarding Hospital Supply Status for Hospital Pharmaceuticals included in Schedule Two but may not propose awarding Sole Subsidised Supply Status in the community; PHARMAC reserves the right: o not to accept any ACP; and/or o not to provide reasons for the acceptance or non-acceptance of any ACP; and/or o to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter; and



ACPs are due by 5pm, Thursday 16 August 2012. PHARMAC may not consider any ACPs that are submitted after this date.

A518829 - qA25122

Usage data for “PCT only” products This year we will be providing “PCT only” usage data prior to the release of the 2012/13 Tender (as shown below). These volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item.

Usage data for 2011 FYR

Chemical Bortezomib* Cisplatin Inj 3.5 mg Inj 100 mg Inj 50 mg Inj 100 mg Inj 2 g Inj 1 g Inj 500 mg Inj 200 mg

Formulation

Units^ 5,428 3,202 1,179 143 8,147 6,892 0 4,560 1 2,760 32 261 9,298 4,452 94 18 5,756 1,797 2,673 58 1,083 447 0 113,640 4,349 3,210

Cytarabine

Dacarbazine Fluorouracil Sodium

Inj 50 mg per ml, 50 ml Inj 50 mg per ml, 10 ml Inj 50 mg per ml, 100 ml Inj 50 mg per ml, 20 ml Inj 200 mg Inj 1 g Cap 10 mg Cap 5 mg

Gemcitabine Hydrochloride

Idarubicin Hydrochloride

Mesna

Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 4 ml Tab 400 mg Tab 600 mg Inj 5 mg Inj 2 mg per ml, 10 ml Cap 100 mg Cap 50 mg Inj 1 mg per ml, 2 ml Inj 1 mg per ml, 1 ml

Mitomycin C Mitozantrone Thalidomide Vincristine Sulphate

*Bortezomib usage data is for 2012 FYR and includes forecast data ^Units is per injections, vials, capsules or tablets

A518829 - qA25122

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Aciclovir Tab dispersible 200 mg 1,050,417 $83,193 $0.0792 C H 1%

Market size may be affected in the event all presentations of valaciclovir becomes fully funded without restrictions Market size may be affected in the event all presentations of valaciclovir becomes fully funded without restrictions Market size may be affected in the event all presentations of valaciclovir becomes fully funded without restrictions

Units

Cost

Unit Subsidy

DV Limit

Comments

Tab dispersible 400 mg

4,591,618

$544,435

$0.1186

C H

Tab dispersible 800 mg

759,449

$160,135

$0.2109

C H

Adapalene Crm 0.1% 165,930 $126,605 $0.7630 C 1%

Galderma has subsidy and delisting protection until 1 July 2013 Galderma has subsidy and delisting protection until 1 July 2013

Gel 0.1%

295,020

$225,100

$0.7630

Alprazolam Tab 250 mcg 415,344 $26,167 $0.0630 C 1%

Arrow has subsidy and delisting protection until 1 July 2012 Arrow has subsidy and delisting protection until 1 July 2012 Arrow has subsidy and delisting protection until 1 July 2012

Tab 500 mcg

390,898

$32,054

$0.0820

Tab 1 mg

120,997

$17,545

$0.1450

Amisulpride Oral liq 100 mg per ml Tab 100 mg Tab 200 mg Tab 400 mg Amoxycillin Cap 250 mg Cap 500 mg Ascorbic Acid Tab 100 mg Aspirin Tab 100 mg Tab dispersible or soluble 300 mg Azathioprine Inj 50 mg Tab 50 mg 30 3,805,711 $1,800 $702,154 $60.0000 $0.1845 C H C H 1% 1% 108,654,099 2,013,852 $1,536,523 $43,298 $0.0141 $0.0215 C H C 1% 1% 2,945,890 $81,307 $0.0276 C H 1% 1,721,726 11,841,383 $55,715 $627,593 $0.0324 $0.0530 C H C H 1% 1% 420 186,824 169,122 39,714 $388 $140,242 $273,498 $122,716 $0.9240 $0.7507 $1.6172 $3.0900 C H C H C H C H 1% 1% 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Bacillus Calmette-Guérin (BCG) Vaccine Inj containing equal to or greater than 500 million CFU Baclofen Oral liq 1 mg per ml C H 1%

Not currently listed on the Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

H PCT 1%

Beclomethasone Dipropionate Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Benzbromarone Tab 100 mg C H 1%

Not currently listed on Pharmaceutical Schedule

11,681,600 32,144,200

$137,259 $395,374

$0.0118 $0.0123

C C

1% 1%

Benzoyl Peroxide Gel 2.5% Gel 5% C H C H 1% 1%

Not currently listed on Pharmaceutical Schedule Not currently listed on Pharmaceutical Schedule

Betamethasone Valerate Scalp app 0.1% Bimatoprost with timolol Eye Drops 0.03% with timolol 0.5% C H 1%

Not currently listed on Pharmaceutical Schedule

2,971,300

$214,528

$0.0722

C H

Bisacodyl Tab 5 mg Bisoprolol Fumarate Tab 2.5 mg Tab 5 mg Tab 10 mg Bortezomib Inj 3.5 mg H PCT 1%

Janssen-Cilag has subsidy and delisting protection until 1 December 2013. Confidential rebate currently exists

1,448,429

$36,138

$0.0250

C H

$0.1293 $0.1580 $0.3060

C H C H C H

1% 1% 1%

Bosentan Tab 125 mg 14,108 $1,078,086 $76.4167 C H 1%

Actelion has subsidy and delisting protection until 1 January 2014. Rebate currently exists. Actelion has subsidy and delisting protection until 1 January 2014. Rebate currently exists.

Tab 62.5 mg

1,426

$108,970

$76.4167

C H

Budesonide Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose 5,633,200 20,761,600 $66,190 $270,939 $0.0118 $0.0131 C C 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Capecitabine Tab 150 mg 111,709 $214,109 $1.9167

+ C H

Units

Cost

Unit Subsidy

DV Limit

Comments

Roche has subsidy and delisting protection until 1 January 2014. Confidential rebate currently exists. Any listing may be subject to a Special Authority restriction. Roche has subsidy and delisting protection until 1 January 2014. Confidential rebate currently exists. Any listing may be subject to a Special Authority restriction.

Tab 500 mg

678,456

$3,985,929

$5.8750

+ C H

Captopril Oral liq 5 mg per ml Tab 12.5 mg Tab 25 mg Tab 50 mg Cefaclor Monohydrate Cap 250 mg Grans for oral liq 125 mg per 5 ml Ceftriaxone Sodium Inj 500 mg Inj 1 g Inf 2 g Cephalexin monohydrate Cap 500 mg 106,408 $47,352 $0.4450 C H 1%

ABM has subsidy and delisting protection until 1 July 2013

170,145 315,658 602,395 478,039

$170,127 $6,313 $14,457 $16,731

$0.9999 $0.0200 $0.0240 $0.0350

C H C H C H C H

1% 1% 1% 1%

4,412,050 10,989,104

$1,084,041 $387,915

$0.2457 $0.0353

C H C H

1% 1%

2,843 4,042

$7,676 $8,480

$2.7000 $2.0980

C H C H H

1% 1% 1%

Cetomacrogol Crm BP Cholecalciferol Tab 1.25 mg (50,000 iu) 1,987,623 $1,285,330 $0.6467 C H 1%

API has subsidy and delisting protection until 1 January 2013

25,975,072

$163,643

$0.0063

Cilazapril Tab 0.5 mg - 1 mg Tab 2.5 mg Tab 5 mg Cilazapril with Hydrochlorothiazide Tab 5 mg with Hydrochlorothiazide 12.5 mg Ciprofloxacin Inj 2 mg per ml, 100 ml Cisplatin Inj 50 mg H PCT 1% H 1% 20,200,139 $3,866,884 $0.1914 C H 1% 16,973,975 19,393,793 19,523,928 $537,509 $1,331,707 $2,134,616 $0.0317 $0.0687 $0.1093 C H C H C H 1% 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Cisplatin Inj 100 mg Clindamycin Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml 665,597 336 $411,838 $5,376 $0.6188 $16.0000 C H C H 1% 1%

Pfizer has subsidy and delisting protection until 1 July 2013

Units

Cost

Unit Subsidy

DV Limit

Comments

H PCT 1%

Clobetasol Propionate Crm 0.05% (pack size 30 g or less) Oint 0.05% (pack size 30 g or less) Scalp app 0.05% Clomiphene Citrate Tab 50 mg 79,770 $238,034 $2.9840 C H 1%

Serono has subsidy and delisting protection until 1 July 2013

3,452,130 3,400,350 609,870

$400,447 $394,441 $129,292

$0.1160 $0.1160 $0.2120

C H C H C H

1% 1% 1%

Clopidogrel Tab 75 mg Clotrimazole Vaginal crm 1% with applicators Vaginal crm 2% with applicators Coal Tar Soln BP Colchicine Tab 500 mcg - 600 mcg Compound Electrolytes Powder for soln for oral use Co-Trimoxazole Tab trimethoprim 80 mg and sulphamethoxazole 400 mg Cyclophosphamide Tab 50 mg Cyclosporin Cap 25 mg 1,135,274 $1,350,976 $1.1900 C H 1%

A confidential rebate currently exists. Bids would need to be for a product bioequivalent to Neoral. Microemulsion formulation preferred. A confidential rebate currently exists. Bids would need to be for a product bioequivalent to Neoral. Microemulsion formulation preferred.

3,217,325

$580,906

$0.1806

C H

2,113,125 1,239,260

$78,488 $154,908

$0.0371 $0.1250

C H C H

1% 1%

182,002

$11,785

$0.0648

3,555,208

$341,300

$0.0960

C H

953,342

$219,269

$0.2300

3,366,341

$141,184

$0.0419

C H

100,504

$51,679

$0.5142

C H PCT 1%

Cap 50 mg

387,900

$919,633

$2.3708

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Cyclosporin Cap 100 mg 530,732 $2,516,519 $4.7416 C H 1%

A confidential rebate currently exists. Bids would need to be for a product bioequivalent to Neoral. Microemulsion formulation preferred.

Units

Cost

Unit Subsidy

DV Limit

Comments

Cytarabine Inj 100 mg Inj 500 mg Inj 1 g Inj 2 g Dacarbazine Inj 200 mg Dexamethasone Eye drops 0.1 % Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Dextrose with Electrolytes Soln with electrolytes Dihydrocodeine Tartrate Tab long-acting 60 mg Dimethicone Crm 5% Crm 10% BPC C H C H 1% 1%

Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule

H PCT 1% H PCT 1% H PCT 1% H PCT 1%

H PCT 1%

120,660

$108,594

$0.9000

C H

42,857 68,799

$184,285 $426,554

$4.3000 $6.2000

C H C H

1% 1%

94,661,000

$638,962

$0.0068

5,430,144

$2,468,000

$0.4545

C H

Docusate Sodium with Sennosides Tab 50 mg with total sennosides 8 mg Dorzolamide Hydrochloride with Timolol Maleate Eye drops 2% with timolol maleate 0.5% 347,955 $1,078,661 $3.1000 C H 1%

MSD has subsidy and delisting protection until 1 January 2014

34,575,703

$1,102,965

$0.0319

C H

Doxorubicin Inj pegylated liposomal 20 mg H PCT 1%

Inj pegylated liposomal 50 mg

H PCT 1%

Erythromycin Ethyl Succinate Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml 6,955,857 4,601,421 $302,580 $269,183 $0.0435 $0.0585 C H C H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Erythromycin Ethyl Succinate Tab 400 mg Escitalopram Tab 10 mg Tab 20 mg Ferrous Salts Oral liq Flecainide Acetate Cap long-acting 100 mg Cap long-acting 200 mg Inj 10 mg per ml, 15 ml Tab 50 mg Tab 100 mg Fluconazole Inj 2 mg per ml, 50 ml Inj 2 mg per ml, 100 ml Fluorouracil Sodium Inj 50 mg per ml, 10 ml Inj 50 mg per ml, 20 ml Inj 50 mg per ml, 50 ml Inj 50 mg per ml, 100 ml Fluoxetine Hydrochloride Cap 20 mg Tab dispersible 20 mg, scored Flutamide Tab 250 mg Fusidic Acid Crm 2 % Oint 2 % Gemcitabine Hydrochloride Inj 200 mg Inj 1 g H PCT 1% H PCT 1%

Any listing may be subject to Special Authority restriction Any listing may be subject to Special Authority restriction

Units

Cost

Unit Subsidy

DV Limit

Comments

4,835,129

$819,554

$0.1695

C H

242,103 137,586

$22,913 $20,638

$0.0946 $0.1500

C H C H

1% 1%

3,978,430

$81,956

$0.0206

C H

702,780 614,168 366 218,157 205,151

$1,073,379 $1,656,616 $3,839 $166,599 $276,680

$1.5273 $2.6973 $10.4900 $0.7637 $1.3487

C H C H C H C H C H

1% 1% 1% 1% 1%

H H

1% 1%

H PCT 1% H PCT 1% H PCT 1% H PCT 1%

22,777,876 955,567

$732,146 $79,631

$0.0321 $0.0833

C H C H

1% 1%

379,594

$208,777

$0.5500

C H

1,807,575 1,335,270

$391,641 $289,309

$0.2167 $0.2167

C H C H

1% 1%

Gemfibrozil Tab 600 mg 83,828 $19,560 $0.2333 C H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Gestrinone Cap 2.5 mg Glycerol Liq BP Haloperidol Inj 5 mg per ml, 1 ml Oral liq 2 mg per ml Tab 500 mcg Tab 1.5 mg Tab 5 mg Heparin Sodium Inj 100 iu per ml, 250 ml Heparinised Saline Inj 100 iu per ml, 2 ml ampoule Inj 100 iu per ml, 5 ml ampoule Hydrocortisone Inj 50 mg per ml, 2 ml Hydrocortisone Butyrate Milky Emulsion 0.1% (pack size 30 g or less) Oint 0.1% (pack size 30 g or less) C H C H 1% 1%

Not currently listed on Pharmaceutical Schedule Not currently listed on Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

4,640

$59,085

$12.7338

C H

1,304,356

$11,648

$0.0089

C H

43,548 76,312 1,229,733 234,111 237,126

$81,609 $15,163 $66,652 $19,197 $61,273

$1.8740 $0.1987 $0.0542 $0.0820 $0.2584

C H C H C H C H C H

1% 1% 1% 1% 1%

H H

1% 1%

6,720

$26,813

$3.9900

C H

Hydrocortisone with Miconazole Crm 1% with miconazole nitrate 2% Hydrocortisone with Natamycin and Neomycin Crm 1% with natamycin 1% and neomycin sulphate 0.5% Oint 1% with natamycin 1% and neomycin sulphate 0.5% Hyoscine (Scopolamine) Patches, 1.5 mg 17,369 $103,780 $5.9750 C 1%

Novartis has subsidy and delisting protection until 1 July 2013

4,139,850

$579,579

$0.1400

2,303,310

$428,416

$0.1860

C H

868,440

$161,530

$0.1860

C H

Hypromellose Eye drops 0.3% with dextran Ibuprofen Oral liq 100 mg per 5 ml Idarubicin Hydrochloride Cap 5 mg H PCT 1% 31,876,233 $428,735 $0.0135 C H 1% 1,638,990 $286,332 $0.1747 C H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Idarubicin Hydrochloride Cap 10 mg Iloprost Inj 100 µg per ml, 0.5 ml Nebuliser soln 10 mcg per ml, 2 ml Indapamide Tab 2.5 mg Indomethacin Cap 25 mg Cap 50 mg Cap long-acting 75 mg C H C H C H 1% 1% 1%

Not currently listed on Pharmaceutical Schedule Not currently listed on Pharmaceutical Schedule Not currently listed on Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

H PCT 1%

H 10,230 $404,085 $39.5000 C H

1% 1%

Rebate currently exists

1,743,703

$57,155

$0.0328

C H

Ipratropium Bromide Aqueous nasal spray, 0.03% Nebuliser soln, 250 mcg per 1 ml Nebuliser soln, 500 mcg per 2 ml Itraconazole Cap 100 mg Lactulose Oral liq 10 g per 15 ml Lamivudine Oral liq 10 mg per ml Tab 150 mg Latanoprost with timolol Eye drops 50 mcg per ml with timolol 0.5% C H 1%

Not currently listed on Pharmaceutical Schedule

746,970 80,872 308,909

$200,686 $15,325 $62,709

$0.2687 $0.1895 $0.2030

C C H C H

1% 1% 1%

540,968

$153,274

$0.2833

C H

196,349,144

$1,507,961

$0.0077

C H

20,160 27,262

$4,200 $69,791

$0.2083 $2.5600

C C

1% 1%

L-Carnitine Inj 200 mg per ml C H 1%

Not currently listed on Pharmaceutical Schedule. Listing may be subject to Special Authority criteria Not currently listed on Pharmaceutical Schedule. Listing may be subject to Special Authority criteria Not currently listed on Pharmaceutical Schedule. Listing may be subject to Special Authority criteria

Oral liquid 500 mg per 15 ml

C H

Powder

C H

Levonorgestrel Tab 750 mcg - 1.5 mg 60,369 $754,613 $12.5000 C H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Lignocaine Hydrochloride Inj 1%, 5 ml Inj 1%, 20 ml Pump spray 10%, 50 ml CFC-free Lignocaine Hydrochloride with Adrenaline Inj 1% with 1:100,000 of adrenaline, 5 ml Inj 1% with 1:200,000 of adrenaline, 20 ml Inj 2% with 1:200,000 of adrenaline, 20 ml Lignocaine with Prilocaine Hydrochloride Crm 2.5% with prilocaine hydrochloride 2.5% 5 g Crm 2.5% with prilocaine hydrochloride 2.5% 30 g Patch 2.5% with prilocaine 2.5% Loperamide Hydrochloride Cap 2 mg Loratadine Oral liq 1 mg per ml Tab 10 mg Lorazepam Tab 1 mg Tab 2.5 mg Malathion Liq 0.5% Shampoo 1% Medroxyprogesterone Acetate Inj 150 mg per ml 1 ml syringe 151,331 $1,082,017 $7.1500 C H 1%

Pfizer has subsidy and delisting protection until 1 July 2013 Pfizer has subsidy and delisting protection until 1 July 2013 Pfizer has subsidy and delisting protection until 1 July 2013 Pfizer has subsidy and delisting protection until 1 July 2013 Pfizer has subsidy and delisting protection until 1 July 2013 Pfizer has subsidy and delisting protection until 1 July 2013

Units

Cost

Unit Subsidy

DV Limit

Comments

90,350 3,526

$63,245 $14,104

$0.7000 $4.0000

C C H

1% 1% 1%

H H H

1% 1% 1%

1,167 3,240

$10,503 $4,860

$9.0000 $1.5000

C H C H

1% 1%

1,462,996

$32,735

$0.0224

C H

12,336,054 19,140,417

$382,418 $400,035

$0.0310 $0.0209

C H C H

1% 1%

5,558,680 312,317

$365,094 $34,886

$0.0657 $0.1117

C H C H

1% 1%

10,976,800 693,600

$208,010 $65,430

$0.0190 $0.0943

C C

1% 1%

Tab 2.5 mg

328,096

$33,794

$0.1030

C H

Tab 5 mg

551,726

$72,055

$0.1306

C H

Tab 10 mg

945,990

$216,001

$0.2283

C H

Tab 100 mg

42,491

$41,004

$0.9650

C H

Tab 200 mg

2,425

$5,699

$2.3500

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Mercaptopurine Tab 50 mg Mesalazine Tab EC 500 mg Mesna Inj 100 mg per ml, 4 ml Inj 100 mg per ml, 10 ml Tab 400 mg Tab 600 mg Methadone Hydrochloride Tab 5 mg Methotrexate Inj 25 mg per ml, 2 ml Inj 25 mg per ml, 20 ml Inj 7.5 mg prefilled syringe 8,754 162 $84,038 $14,580 $9.6000 $90.0000 C H C H C H 1% 1% 1%

Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction

Units

Cost

Unit Subsidy

DV Limit

Comments

261,194

$491,672

$1.8824

C H PCT 1%

146,798

$72,665

$0.4950

C H

H PCT 1% H PCT 1% H PCT 1% H PCT 1%

2,143,818

$396,606

$0.1850

C H

Inj 10 mg prefilled syringe

C H

Inj 20 mg prefilled syringe

C H

Inj 25 mg prefilled syringe

C H

Inj 30 mg prefilled syringe

C H

Inj 40 mg prefilled syringe

C H

Minocycline Hydrochloride Tab 50 mg Mitomycin C Inj 5 mg $72.7500 C H PCT 1%

Arrow has subsidy and delisting protection until 1 July 2013

1,084,104

$104,616

$0.0965

C H

Mitozantrone Inj 2 mg per ml, 10 ml Morphine Sulphate Cap long-acting 10 mg 2,869,638 $637,060 $0.2220 C H 1% H PCT 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Morphine Sulphate Cap long-acting 30 mg Cap long-acting 60 mg Cap long-acting 100 mg Tab long-acting 10 mg Tab long-acting 30 mg Tab long-acting 60 mg Tab long-acting 100 mg Morphine Tartrate Inj 80 mg per ml, 1.5 ml Inj 80 mg per ml, 5 ml Mucilaginous Laxatives Dry Mupirocin Nasal oint 2% Oint 2% Mycophenolate Mofetil Cap 250 mg Inj 500 mg Powder for oral liq 1 g per 5 ml Tab 500 mg Naltrexone Hydrochloride Tab 50 mg Nevirapine Oral suspension 10 mg per ml Nicotinic Acid Tab modified-release 375 mg Tab modified-release 500 mg Tab modified-release 750 mg Tab modified-release 1 g C H C H C H C H 1% 1% 1% 1%

Not currently listed on Pharmaceutical Schedule Not currently listed on Pharmaceutical Schedule Not currently listed on Pharmaceutical Schedule Not currently listed on Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

1,025,515 384,760 264,832 726,968 307,016 179,886 274,717

$328,165 $265,484 $213,190 $143,940 $96,710 $129,518 $215,653

$0.3200 $0.6900 $0.8050 $0.1980 $0.3150 $0.7200 $0.7850

C H C H C H C H C H C H C H

1% 1% 1% 1% 1% 1% 1%

16,581 3,415

$99,486 $51,225

$6.0000 $15.0000

C H C H

1% 1%

64,491,359

$776,476

$0.0120

C H

C H 1,623,930 $714,529 $0.4400 C H

1% 1%

Not currently listed on Pharmaceutical Schedule

547,049

$382,934

$0.7000

C H H H

1% 1% 1% 1%

890,737

$1,247,032

$1.4000

C H

94,788

$388,631

$4.1000

C H

9,600

$5,382

$0.5606

C H

Nitrofurantoin Oral liq 25 mg per 5 ml Tab 50 mg 1,819,131 $403,847 $0.2220 C H C H 1% 1%

Not currently listed on Pharmaceutical Schedule

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Nitrofurantoin Tab 100 mg Nystatin Cap 500,000 u Tab 500,000 u Octreotide (somatostatin analogue) LAR inj 10 mg LAR inj 20 mg LAR inj 30 mg 227 1,340 1,028 $402,358 $3,160,725 $3,033,885 $1,772.5000 $2,358.7500 $2,951.2500 C H C H C H 1% 1% 1%

Confidential rebate currently exists Confidential rebate currently exists Confidential rebate currently exists

Units

Cost

Unit Subsidy

DV Limit

Comments

574,797

$215,549

$0.3750

C H

184,501 62,080

$47,269 $17,581

$0.2562 $0.2832

C H C H

1% 1%

Oestradiol TDDS 25 mcg per day TDDS 50 mcg per day TDDS 75 mcg per day TDDS 100 mcg per day Olanzapine Orodispersible tab 5 mg Orodispersible tab 10 mg Tab 2.5 mg Tab 5 mg Tab 10 mg Ondansetron Tab 4 mg Tab 8 mg Tab disp 4 mg Tab disp 8 mg Oxycodone Hydrochloride Oral liq 5 mg per 5 ml Pantoprazole Tab 20 mg Tab 40 mg Paracetamol Inj 10 mg per ml, 50 ml Inj 10 mg per ml, 100 ml H H 1% 1% 5,388,404 8,114,807 $236,705 $446,314 $0.0439 $0.0550 C H C H 1% 1% 1,441,615 $64,584 $0.0448 C H 1% 140,887 184,183 79,005 27,860 $23,951 $31,311 $13,431 $5,572 $0.1700 $0.1700 $0.1700 $0.2000 C H C H C H C H 1% 1% 1% 1% H H H H H 1% 1% 1% 1% 1% 16,604 $14,632 $0.8813 47,576 47,974 $17,900 $24,707 $0.3763 $0.5150 C C C C 1% 1% 1% 1%

Not currently listed on Pharmaceutical Schedule

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Paraffin Liquid with Soft White Paraffin Eye oint with soft white paraffin Paroxetine Hydrochloride Tab 20 mg Phenobarbitone Oral liq 15 mg per 5 ml C H 1%

Not currently listed on Pharmaceutical Schedule

Units

Cost

Unit Subsidy

DV Limit

Comments

126,515

$131,214

$1.0371

13,406,016

$1,063,544

$0.0793

C H

Phenobarbitone Sodium Inj 200 mg per ml, 1 ml Phenoxymethylpenicillin (Penicillin V) Cap 250 mg Cap 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Pindolol Tab 5 mg Tab 10 mg Tab 15 mg Piperacillin Sodium with Tazobactam Sodium Inj 4 g with tazobactam sodium 500 mg Pipobroman Tab 25 mg H 1%

Not currently listed on the Pharmaceutical Schedule. Tender agreement may be subject to a Special Authority restriction.

591,098 2,717,403 2,270,804 5,246,575

$114,791 $635,872 $38,150 $93,389

$0.1942 $0.2340 $0.0168 $0.0178

C H C H C H C H

1% 1% 1% 1%

227,969 254,452 112,486

$12,310 $23,384 $15,523

$0.0540 $0.0919 $0.1380

C H C H C H

1% 1% 1%

Potassium iodate Tab 268 mcg (150 mcg elemental) Pramipexole Hydrochloride Tab 0.125 mg Tab 0.250 mg Tab 0.5 mg Tab 1 mg $0.0650 $0.0800 $0.1400 C H C H C H C H 1% 1% 1% 1%

Not currently listed on Pharmaceutical Schedule

2,797,070

$234,643

$0.0839

Prilocaine Hydrochloride Inj 0.5%, 50 ml Inj 2%, 5 ml Quinine Sulphate Tab 300 mg 1,626,576 $175,865 $0.1081 C H 1% H H 1% 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Rifabutin Cap 150 mg Ritonavir Oral liq 80 mg per ml Ropinirole Hydrochloride Tab 0.25 mg Tab 1 mg Tab 2 mg Tab 5 mg Ropivacaine Hydrochloride with Fentanyl Inf 2 mg per ml with 2 mcg of fentanyl per ml, 100 ml Inf 2 mg per ml with 2 mcg of fentanyl per ml, 200 ml Rosuvastatin Tab 5 mg C H 1%

Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction. Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction. Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction. Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.

Units

Cost

Unit Subsidy

DV Limit

Comments

10,774

$76,564

$7.1063

C H

$1.1553

C H

542,544 899,057 476,135 72,336

$40,045 $170,714 $141,423 $32,723

$0.0738 $0.1899 $0.2970 $0.4524

C H C H C H C H

1% 1% 1% 1%

Tab 10 mg

C H

Tab 20 mg

C H

Tab 40 mg

C H

Salbutamol Oral liq 2 mg per 5 ml Sertraline Tab 50 mg Tab 100 mg Sodium Chloride Inj 0.9%, 5 ml 146,527 $45,423 $0.3100 C H 1%

Multichem has subsidy and delisting protection until 1 July 2013 Multichem has subsidy and delisting protection until 1 July 2013 Multichem has subsidy and delisting protection until 1 July 2013

990,002

$13,134

$0.0133

C H

222,492 41,594

$13,350 $4,437

$0.0600 $0.1067

C H C H

1% 1%

Inj 0.9%, 10 ml

568,750

$176,313

$0.3100

C H

Inj 0.9%, 20 ml

146,527

$115,268

$0.7867

C H

Inj 23.4%, 20 ml

4,233

$26,456

$6.2500

C H

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Sodium Citrate with Sodium Lauryl Sulphoacetate Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml Sodium Citro-Tartrate Grans effervescent 4 g sachets Sodium Cromoglycate Eye drops 2% Nasal spray, 4% Sodium Fluorescein Inj 100 mg per ml Solifenacin succinate Tab 5 mg 968,610 $1,824,216 $1.8833 C H 1%

CSL has subsidy and delisting protection until 1 January 2013. Rebate currently exists CSL has subsidy and delisting protection until 1 January 2013. Rebate currently exists

Units

Cost

Unit Subsidy

DV Limit

Comments

384,814

$192,407

$0.5000

C H

1,655,355

$160,215

$0.0968

447,160 58,586

$105,530 $42,209

$0.2360 $0.7205

C C

1% 1%

Tab 10 mg

165,885

$312,417

$1.8833

C H

Spironolactone Tab 25 mg Tab 100 mg Sulindac Tab 100 mg Tab 200 mg Sulphasalazine Tab 500 mg 255,272 $29,816 $0.1168 C H 1%

Pfizer has subsidy and delisting protection until 1 July 2013 Pfizer has subsidy and delisting protection until 1 July 2013

5,569,049 1,343,302

$256,176 $203,510

$0.0460 $0.1515

C H C H

1% 1%

66,513 95,341

$3,538 $6,407

$0.0532 $0.0672

C H C H

1% 1%

Tab EC 500 mg

6,183,520

$797,056

$0.1289

C H

Tamsulosin Tab 400 mcg Temozolomide Cap 5 mg Cap 20 mg Cap 100 mg Cap 250 mg Tenoxicam Inj 20 mg Terazosin Hydrochloride Tab 1 mg 163,381 $8,753 $0.0536 C H 1% H 1% 5,103 10,083 13,307 494 $16,330 $145,195 $931,490 $81,016 $3.2000 $14.4000 $70.0000 $164.0000 C H C H C H C H 1% 1% 1% 1% 155,169 $30,930 $0.1993 C H 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Terazosin Hydrochloride Tab 2 mg Tab 5 mg Tetrabenazine Tab 25 mg Thalidomide Cap 50 mg Cap 100 mg Theophylline Oral liq 80 mg per 15 ml Tab long-acting 250 mg Timolol Maleate Eye drops 0.25%, gel forming Eye drops 0.5%, gel forming 30,708 54,207 $40,535 $81,961 $1.3200 $1.5120 C H C H 1% 1%

MSD has subsidy and delisting protection until 1 January 2014 MSD has subsidy and delisting protection until 1 January 2014

Units

Cost

Unit Subsidy

DV Limit

Comments

4,347,919 3,088,282

$124,226 $110,296

$0.0286 $0.0357

C H C H

1% 1%

118,111

$187,712

$1.5893

C H

H PCT 1% H PCT 1%

100,036 1,052,864

$3,101 $226,471

$0.0310 $0.2151

C H C H

1% 1%

Tranexamic Acid Tab 500 mg Travoprost with timolol Eye drops 0.004% with timolol 0.5% C H 1%

Not currently listed on Pharmaceutical Schedule

1,932,848

$636,294

$0.3292

C H

Tretinoin Crm 0.5 mg per g 550,250 $152,970 $0.2780 C 1%

Valeant has subsidy and delisting protection until 1 July 2013

Triamcinolone acetonide with gramicidin, neomycin and nystatin Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Tropisetron Cap 5 mg 2,722 $42,142 $15.4820 C H 1%

Any listing may be subject to a Special Authority restriction

555,900

$129,339

$0.2327

C H

Any listing may be subject to a Special Authority restriction

Valaciclovir Tab 250 mg C H 1%

Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction GSK has subsidy and delisting protection until 1 January 2014 Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction

Tab 500 mg Tab 1000 mg

35,573

$121,802

$3.4240

C H C H

1% 1%

Vincristine Sulphate Inj 1 mg per ml, 1 ml H PCT 1%

SCHEDULE TWO: PRODUCTS TO BE TENDERED (DRAFT)

Chemical Name Line Item Vincristine Sulphate Inj 1 mg per ml, 2 ml Vitamin B Complex (BPC, strong) Tab Vitamins Cap (fat soluble vitamins A, D, E, K) 147,279 $57,439 $0.3900 C 1%

Pharmaco has subsidy and delisting protection until 1 March 2013

Units

Cost

Unit Subsidy

DV Limit

Comments

H PCT 1%

2,798,013

$26,301

$0.0094

Vitamins (BPC cap strength) Tab Water for Injection Purified for inj 5 ml Purified for inj 10 ml Purified for inj 20 ml Zidovudine (AZT) Cap 100 mg Oral liq 10 mg per ml Ziprasidone Cap 20 mg Cap 40 mg Cap 60 mg Cap 80 mg Zoledronic Acid Inj 4 mg H 1%

Novartis has subsidy and delisting protection until 1 July 2012. A confidential rebate currently exists. Novartis has subsidy and delisting protection until 1 September 2013

21,491,071

$171,929

$0.0080

24,670 233,727 55,144

$4,539 $47,680 $13,786

$0.1840 $0.2040 $0.2500

C H C H C H

1% 1% 1%

39,071 22,000

$56,653 $3,190

$1.4500 $0.1450

C H C H

1% 1%

175,105 148,382 32,659 55,820

$256,469 $407,506 $134,539 $306,601

$1.4647 $2.7463 $4.1195 $5.4927

C H C H C H C H

1% 1% 1% 1%

Soln for infusion 5 mg in 100 ml

173,928

$1,043,568

$6.0000

C H

Metadata

Title

2012/13 Tender Consultation - Suppliers; Contact: Marcus Kim

Abstract

19 July 2012 2012/13 Invitation to Tender PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on:    A proposal to tender certain pharmaceuticals for sole supply; The draft process and terms and conditions for the 2012/13…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.